Jeff Bezos' newly unveiled AI startup Prometheus raised $12B at a $41B valuation to compress engineering cycles by 10x or more. For the space sector, this means rocket, satellite, and lander development could shrink from decades to years, with direct implications for Blue Origin and the broader aerospace race.
Prometheus, the AI startup by Jeff Bezos and Vik Bajaj, raised $12 billion in its second round at a $41 billion valuation—all while still in stealth and with just 150 employees. It's arguably the most capital ever given to an unreleased product.
Prometheus, with $12 billion in fresh funding, aims to build an 'artificial general engineer'—an AGI that can autonomously design and manufacture physical systems, from jet engines to pharmaceuticals. This could be the most ambitious applied AI project ever.
Jeff Bezos’s Prometheus raises $12B to build an artificial general engineer, promising to autonomously design and optimize complex physical systems—including supply chain infrastructure. This could revolutionize manufacturing logistics and production planning.
Prometheus's $12B raise envisions an artificial general engineer that can design drug compounds autonomously, potentially cutting years from pharmaceutical R&D. The startup's biotech roots via co-founder Vik Bajaj of Verily add credibility.
The Milken Institute Global Conference highlighted key economic indicators and policy shifts, with projections of 2.5% global GDP growth influencing investor strategies. Finance leaders discussed Federal Reserve actions and commodity price fluctuations, offering insights into market volatility and regulatory impacts. This event underscores the need for adaptive investment approaches amid rising digital asset trends.
Financial institutions are transitioning from passive transaction processors to active guardians of senior wealth, deploying AI-driven anomaly detection and specialized staff training to combat a multi-billion dollar elder fraud crisis.
While consumers fixate on the visible pain of rising gas prices, a more insidious economic force—stagflation—is emerging as the primary threat to market stability. Recent Federal Reserve warnings suggest that persistent inflation and surging yields may trigger a valuation trap that the stock market has yet to fully price in.
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Investors are evaluating JPMorgan Chase as a strategic buy ahead of its April 14 earnings report, which serves as the traditional bellwether for the global banking sector. The upcoming results will provide critical insights into net interest income trends and the resilience of the U.S. consumer.
Bank of America has reached a settlement with victims of Jeffrey Epstein, resolving long-standing claims that the financial institution failed to flag suspicious activity related to the deceased financier's sex-trafficking ring. The agreement follows similar high-profile settlements by JPMorgan Chase and Deutsche Bank, marking a significant step in the banking industry's effort to move past the Epstein scandal.
Bank of America has reached a settlement to resolve claims brought by victims of Jeffrey Epstein, following allegations that the institution failed to flag suspicious financial activity. The agreement marks a significant conclusion to the industry-wide legal fallout regarding the banking sector's ties to the disgraced financier.
A massive sell-off in Trump-affiliated digital assets has erased billions in market capitalization following a breakdown in legislative talks and increasing pressure from traditional financial institutions. The collapse of the 'Trump coin' ecosystem marks one of the most significant volatility events in the 2026 crypto market.
YieldMax has announced its latest monthly dividend distributions across its suite of option income strategy ETFs, including its Bitcoin and Robinhood-linked funds. These payouts highlight the ongoing demand for high-yield synthetic covered call strategies in both the digital asset and traditional equity sectors.
YieldMax has announced its latest monthly dividend distributions for several of its popular option income strategy ETFs, including those tracking JPMorgan, ExxonMobil, and Robinhood. The payouts reflect the volatility-harvesting nature of the funds, with the Robinhood-linked ETF leading the group in distribution size.
JPMorgan Chase CEO Jamie Dimon has cautioned that persistent inflation, fueled by escalating geopolitical tensions involving Iran, remains the primary threat to the U.S. economic expansion. Speaking in Miami, Dimon highlighted the risk of a 'skunk at the party' that could force interest rates to remain higher than markets currently anticipate.
Gentry Private Wealth LLC has disclosed a new $2.27 million stake in the JPMorgan Ultra-Short Income ETF (JPST), acquiring over 44,000 shares. This move reflects a strategic shift toward high-liquidity, low-duration fixed income assets as institutional investors navigate a complex interest rate environment.
Syon Capital LLC has established a new stake in Italian energy giant Eni SpA, acquiring nearly 14,000 shares valued at approximately $489,000. This move aligns with a broader trend of institutional investors recalibrating portfolios toward high-yield European energy majors as global energy markets stabilize.
JPMorgan Chase analysts suggest that the prohibitive costs of artificial intelligence integration will force smaller financial institutions into defensive mergers. As AI becomes essential for operational efficiency and risk management, the widening technological gap favors megabanks with deep R&D budgets. This shift marks a transition where compute power and data scale are becoming as critical as capital reserves for survival.